Sign In
Buy ERAS
$18.53
-0.650 (-3.39%)
At Close: Jul 10, 2026
Hallador Energy Advances Expansion into Natural Gas Power Generation through ERAS Application
04:05pm, Tuesday, 16'th Dec 2025
TERRE HAUTE, Ind., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today announced that the Company has finalized its application into th
Erasca to Present at the 8th Annual Evercore Healthcare Conference
09:08am, Tuesday, 25'th Nov 2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca Reports Third Quarter 2025 Business Updates and Financial Results
04:01pm, Wednesday, 12'th Nov 2025
U.S. composition of matter patent protection through 2043 for potential best-in-class pan-RAS molecular glue ERAS-0015 Strengthened scientific leadership with promotion of Robert Shoemaker, Ph.D., to
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
08:00am, Thursday, 06'th Nov 2025
The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001
Erasca to Present at Upcoming Conferences in November
08:00am, Tuesday, 04'th Nov 2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
08:00am, Tuesday, 02'nd Sep 2025
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
04:01pm, Tuesday, 12'th Aug 2025
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balanc
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
08:00am, Monday, 02'nd Jun 2025
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs exp
Erasca to Present at Upcoming Investor Conferences in June
08:00am, Thursday, 29'th May 2025
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca Reports First Quarter 2025 Business Updates and Financial Results
04:05pm, Tuesday, 13'th May 2025
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026
IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful exte
Erasca to Present at the Bank of America Securities Health Care Conference
08:00am, Wednesday, 07'th May 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
04:05pm, Tuesday, 29'th Apr 2025
ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with
Erasca, Inc.: Carving A Different Niche In RAS Signaling
11:33am, Friday, 25'th Apr 2025
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, na
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
04:31pm, Tuesday, 25'th Mar 2025
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex in
